Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 12-Month High – What’s Next?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $30.91 and last traded at $29.81, with a volume of 99279 shares trading hands. The stock had previously closed at $28.98.

Chugai Pharmaceutical Trading Up 2.9 %

The stock has a market cap of $98.11 billion, a PE ratio of 38.71 and a beta of 0.76. The business has a 50-day moving average price of $24.67 and a 200 day moving average price of $23.18.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.19 EPS for the quarter. The business had revenue of $1.89 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.